Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose FSH-GEX(TM) in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects from 18-40 years of age at screening.~2. Subjects must be in good health as determined by medical and gynecological history, physical and gynecological examination, vital signs, body measurements, electrocardiogram, and laboratory tests~3. Subjects must be willing to use additional non-hormonal contraception~4. Subjects must have used a combined oral contraceptive, combined contraceptive vaginal ring or combined contraceptive patch~5. Vital signs which are within the following ranges: systolic blood pressure between 90-140 mmHg, diastolic blood pressure between 50-90 mmHg, pulse rate between 40 - 100 bpm~6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.9 kg/m2~7. Able to provide written informed consent prior to study participation.~8. Able to communicate well with the investigator and to understand and comply with the requirements of the study.~Exclusion Criteria:~1. Smokers of more than 5 cigarettes per day.~2. Average daily intake of more than 3 units of alcohol per day (where 1 unit equals 250 mL of beer, 125 mL of wine or 25 mL of spirits) or an average weekly intake of more than 21 units alcohol.~3. Use of any prescription drug or over-the-counter medication from screening until the end-of-study visit, without prior approval of the investigator. Paracetamol® is acceptable without prior approval.~4. Any drugs that may reduce the effectiveness of combination oral contraceptive (COC) from screening until the end-of-study visit~5. Administration of any investigational product or use of any investigational device within 30 days prior to Screening.~6. Donation or loss of 500 mL or more of blood within 90 days prior to first dosing of FSH-GEX(TM).~7. History of acute or chronic bronchospastic disease~8. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic allergy. A known hypersensitivity to any of the study drugs.~9. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of drugs or which may jeopardize the subject in case of participation in the study.~10. History or presence of any malignancy.~11. Determined or suspected pregnancy.~12. Breast feeding women.~13. History of (or current) endocrine abnormalities~14. Contraindication for the use of oral contraceptives~15. Contraindication for the use of follitropin alfa, follicle-stimulating hormone (FSH) or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin; ovarian, uterine, or mammary carcinoma).~16. Porphyria or family history of porphyria.~17. History of ovarian surgery.~18. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound investigation.~19. An abnormal cervical smear~20. History or presence of an immune-compromising disease, or a positive human immunodeficiency virus (HIV) test result in the past or at the screening visit.~21. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at the screening visit.~22. History of drug or alcohol abuse within the 12 months prior to the screening visit or evidence of such abuse~23. Planned surgery or hospitalization during the period of the study.~24. Concurrent participation or participation within 30 days before screening in another clinical trial, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study or previous participation in the 104676-CS0160 (FSH-GEXTM) study.~25. Injection of one or more doses of any depot contraceptive drug /drug combination ≤10 months prior to screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- FSH-GEX 75 IU (Type: EXPERIMENTAL): follitropin epsilon 75 IU QD
- FSH-GEX 150 IU (Type: EXPERIMENTAL): follitropin epsilon 150 IU QD
- FSH-GEX 150 IU QAD (Type: EXPERIMENTAL): follitropin epsilon 150 IU QAD
- recombinant FSH (Type: ACTIVE_COMPARATOR): Gonal-f 150 IU QD
- urinary FSH (Type: ACTIVE_COMPARATOR): Bravelle 150 IU QD
- Placebo (Type: PLACEBO_COMPARATOR): Placebo QD

Based on this trial design, predict the completion outcome and termination type (if applicable).